Introduction: Glutamate dysfunction has been implicated in the pathophysiology of schizophrenia. The metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors. GRM7, the gene that encodes mGluR7, is expressed in many regions of the human central nervous system. The GRM7 gene is located on human chromosome 3p26, which has been suggested by linkage analysis to contain a susceptibility locus for schizophrenia.
Introduction
Schizophrenia is a severe psychiatric disorder, which is equally prevalent in men and women and affects approximately one percent of the population worldwide. Several neurotransmitter systems and functional networks within the brain have been found to be affected in patients with schizophrenia. The glutamatergic neuronal dysfunction hypothesis is one of the main explanatory hypotheses (Carlsson et al., 1997) . Glutamate is the primary excitatory neurotransmitter in brain. It is contained as a neurotransmitter in approximately 60% of brain neurons, including almost all cortical pyramidal neurons. Further, virtually 100% of brain neurons contain some type of glutamate receptor. Glutamate mediates its effects on the central nervous system via both ionotropic and metabotropic receptors. The metabotropic glutamate receptors (mGluRs), which are G protein-coupled receptors, are divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties (Nakanishi 1994; Pin and Duvoisin 1995) . The mGluRs in group I are mGluR1 and mGluR5, those in group II are mGluR2 and mGluR3, and those in group III are mGluRs 4, 6, 7, and 8. Group II and group III mGluRs are linked to inhibition of the cyclic AMP cascade but differ in their agonist selectivities. mGluR7 is the most highly conserved mGluR subtype across mammalian species (Flor et al., 1997) . Makoff et al (1996) observed by in situ hybridization that GRM7 is expressed in many areas of the human brain, especially the cerebral cortex, hippocampus, and cerebellum. mGluR7 is localized directly in the presynaptic zone of the synaptic cleft of glutamatergic synapses (Kinoshita et al 1998; Kosinski et al 1999) , where it is thought to act as an autoreceptor that is activated by glutamate released from the presynaptic terminal during action potentials. Furthermore, mGluR7 is thought to be a key player in shaping synaptic responses at glutamatergic synapses as well as in regulating key aspects of inhibitory GABAergic transmission (Kinoshita et al 1998; Kosinski et al 1999) .
mGluR7 has putative roles in anxiety, emotional responses, and spatial working memory (Callaerts-Vegh et al 2006; Cryan et al 2003; Mitsukawa et al 2006) . Cognitive dysfunction is estimated to occur in 75%-85% of patients with schizophrenia, often precedes the onset of other symptoms (Reichenberg et al 2006) . Working memory is one of primary cognitive domains that are crucial for developing targets for the treatment of cognition in schizophrenia (Nuechterlein et al 2004) .
mGluR7 ablation causes dysregulation of the hypothalamic-pituitary-adrenal axis and increases hippocampal BDNF protein levels (Mitsukawa et al 2005) . Dysregulation of BDNF production or release is associated with neuropsychiatric disorders, such as schizophrenia (Kelley 2004; Harrison and Weinberger 2005) . Association between the val66met polymorphism of the BDNF gene and hippocampal volume in human, particularly in patients with schizophrenia (Szeszko PR et al 2005) .
In the present study, we examined the GRM7 gene as a candidate for schizophrenia.
Materials and Methods

Subjects
All subjects were of Japanese descent and were recruited from the main island of Japan. Patients with schizophrenia were diagnosed according to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV). Control subjects were mentally healthy, unrelated subjects with no self-reported family history of mental illness within second-degree relatives. We sequenced the 5' region, exons and exon-intron boundaries of the GRM7 gene in 32 patients (mutation screening patients) with schizophrenia (mean age ± SD, 46.5 ± 10.9 years; 17 men and 15 women) to identify polymorphisms. We then genotyped 576 patients including the mutation screening patients (mean age ± SD, 46.6 ± 14.8 years; 322 men and 254 women) and 576 control subjects (mean age ± SD, 46.8 ± 12.9 years; 268 men and 308 women) (1 st association population) with Predesigned TaqMan single nucleotide polymorphism (SNP) genotyping assays. When Predesigned TaqMan SNP genotyping assays
were not available, we performed direct sequencing of DNAs from 96 patients including the mutation screening patients (mean age ± SD, 50.3 ± 13.1 years; 55 men and 40 women) and 96 control subjects (mean age ± SD, 53.6 ± 9.1 years; 42 men and 54 women). For SNPs for which an association with schizophrenia was suggested in the first association population, we performed genotyping in an independent sample of 1817 patients (mean age ± SD, 45.5 ± 14.1 years; 962 men and 855 women) and 1728 control subjects (mean age ± SD, 46.2 ± 13.6 years; 958 men and 770 women) (confirmation population). The present study was approved by the ethics committees of the University of Tsukuba and participating institutes. All participants provided written informed consent.
DNA isolation and genotyping
DNAs were extracted from peripheral lymphocytes by standard phenol-chloroform extraction. The genomic structure of GRM7 was determined from the University of California at Santa Cruz (UCSC) database (http://genome.ucsc.edu/cgi-bin/hgGateway) and the National 
Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from cultured cells with the SV Total RNA Isolation System (Promega, Madison, WI, USA). cDNA was synthesized from RNA with Revertra Ace (Toyobo, Tokyo, Japan) and oligo dT primer. Expression of GRM7 was quantified by real-time quantitative RT-PCR with the TaqMan Gene Expression Assay and ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) per the manufacturer's instructions. Primers and probes were purchased from Applied Biosystems (Assays-on-Demand Assay ID: Hs00179051_m1). GAPDH was used as an internal control.
Data were collected and analyzed with Sequence Detector Software (SDS) version 2.1 (Applied Biosystems) and the standard curve method.
Luciferase reporter assay
To assay promoter activity of the 5'-flanking region and exon 1 of the GRM7 gene, 9
fragments of the 5' region were cloned into the pGL3-Basic plasmid with and without a (371T/C) in exon 1 of GRM7 showed a potential association for schizophrenia (allelic uncorrected p = 0.04) ( Table 1) . We did not detect a significant association with schizophrenia of any of the other 14 SNPs, including the Tyr433Phe polymorphism (allelic uncorrected p = 0.33; genotypic uncorrected p = 0.63), which was previously reported to be associated (Bolonna et al 2001) . The haplotype blocks consisted of IVS1-76T/C, IVS1-67A/G, and IVS1-23G/A and of 2345C/T and 2384A/G. No significant haplotypic association was suggested for these 2 haplotype blocks (p > 0.05). We confirmed the association of the 371T/C polymorphism with schizophrenia in an independent population of 1717 patients and 1807 control subjects and confirmed the association (allelic p = 0.03, one-sided) ( Table 2 ).
Results
Twenty
The allelic p value of the association in the total population of 2293 patients with schizophrenia and 2382 control subjects was 0.009 (Table 2 ). According to the HapMap database (http://www.hapmap.org/index.html), the 371T/C polymorphism (rs3749380) was not in the LD block and was not in LD with other SNPs within 80 kb (r 2 < 0.7). Weak LD was observed with rs458351 (D' = 0.89 and r 2 = 0.69), which is 30 kb upstream of rs3749380.
Expression of GRM7 mRNA was assessed by RT-PCR in 7 different human cell lines (IMR-32, NH-12, TN-2, NB-1, SCCH-26, A172, and T98G). GRM7 was expressed in NH-12 and SCCH-26 cells (data not shown). Because expression in NH-12 cells was higher than in
SCCH-26 cells, we used NH-12 cells, a human cell line derived from neuroblastoma, for luciferase assays. Dual luciferase assay revealed that the strongest promoter activity for GRM7 was contained in the 1-kb fragment upstream of the ATG site of exon 1. However, a promoter construct containing the sequence from the ATG to the end of exon 1 showed significantly lower activity, indicating that the 371T/C polymorphism is in a regulatory region.
When an SV40 enhancer was added downstream of the luciferase gene, the 371C allele showed significantly higher promoter activity than the 371T allele ( Figure 2) .
Discussion
In the present study, we examined associations between polymorphisms in the GRM7 gene and schizophrenia. Weak association was found for a synonymous SNP (371T/C) in exon 1 in the first association population, and this association was replicated in the confirmation population. The T allele, which is associated with schizophrenia, has lower promoter activity than the C allele. On the basis of this finding, we hypothesized that lower expression of mGluR7 may increase risk of developing schizophrenia, though studies of the expression of GRM7 in brains of patients with schizophrenia have not been reported.
mGluR7 was the first group III mGluR found to be enriched presynaptically at active zones of hippocampal pyramidal cells (Shigemoto et al 1996) . The low affinity of mGluR7 for glutamate suggests that mGluR7 might act as a "low-pass filter" that suppresses release of glutamate only when action potentials arriving at a high frequency produce massive glutamate release. The interaction with PICK1 (protein interacting with PRKCA 1) is crucial for the clustering of mGluR7 at presynaptic release sites (Boudin et al 2000) . PICK1 is reported to be associated with schizophrenia (Dev and Henley 2006; Fujii et al 2006) .
In the present study, we found an association between a functional SNP, 371T/C, in the gene encoding mGluR7 and schizophrenia. Recently, a genome-wide association study of 2000 individuals with bipolar disorder and 3000 control subjects found a strong association of SNP marker rs1485171 (p = 9.7 X 10 -5 ) in GRM7 with bipolar disorder (Consortium 2007; Consortium. 2007) . Therefore, genetic variations in the GRM7 gene may be involved in both schizophrenia and bipolar disorder.
An association between Tyr433Phe polymorphism of GRM7 and schizophrenia was reported (Bolonna et al 2001) . However, we failed to detect the association (allele, p = 0.33; genotype, p = 0.63). Recently, a copy number variation of the GRM7 locus has been reported in patients with schizophrenia (Wilson et al 2006) . In the present study, we did not observe significant deviation from Hardy-Weinberg expectancy of the genotypic distributions of SNPs, indicating that copy number variations at the SNP examined in the present study are not common and are unlikely.
In the present study, the association of 371T/C with schizophrenia was observed in two independent case control populations. However, its weak association (OR = 1.12) requires replication studies in large sample populations of more than 2000 cases and 2000
control subjects with a power greater than 0.8. We believe that GRM7 is an interesting target worth such studies for schizophrenia and other psychiatric disorders. Relative ratio of expression is shown as relative to that of pGL3-Basic, which was set at 1.
The mean ±SEM was calculated from triplicate assays.
(C) Effect of the 371C/T polymorphism on GRM7 promoter activity. This assay was performed with pGL3-enhancer vector, because the constructs that contain GRM7 exon 1
show extremely low luciferase activity. 
